Reading the tape
NASDAQ: BLFS
BioLife Solutions, Inc.
Healthcare · Medical - Instruments & Supplies
Market Cap
$1.05B
52w High
$29.62
52w Low
$17.86
P/E
-84.23
Volume
100.67K
Outstanding Shares
48.86M
Price vs Fundamentals
Why The Stock Is Moving
Likely multiple compressionModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -13.14%Revenue (TTM): 47.35%FCF (TTM): 161.05%P/FCF: 56th pct
What changed
The stock fell 13.14% over the last year. Revenue grew 47.35% over the trailing twelve months. Operating margin moved from -10.92% to -12.61%. Free cash flow grew 161.05% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently -12.61%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally.
CEORoderick de Greef
SectorHealthcare
IndustryMedical - Instruments & Supplies
Employees159
IPO dateNov 22, 1989
Valuation
Forward P/E—
EV/EBITDA-121.55
Enterprise value$1.14B
Stock splits
Jan 29, 2014↓ Reverse
Every 14 shares became 1
Jun 16, 2000↓ Reverse
Every 5 shares became 1
Profitability & growth
Revenue growth-648.63%
Gross margin64.56%▼1.05%vs FY2024
Operating margin-12.61%▼45.46%vs FY2024
ROE-3.26%▲43.62%vs FY2024
Analyst consensus
RatingBuy
Target price$33.00▲54.24%
17
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est $0.01 · Revenue est $25.66M
View